Assessment of apixaban plasma levels by laboratory tests: Suitability of three anti-Xa assays a multicentre french GEHT study

Thrombosis and Haemostasis

Volumn 111, Issue 2, 2013, Pages 240-248

  Gouin Thibault, Isabelle ^a,b   Flaujac, Claire ^b   Delavenne, Xavier ^c   Quenet, Sara ^c   Horellou, Marie Hélenè ^b   Laporte, Silvy ^c   Siguret, Virginie ^d   Lecompte, Thomas ^e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c University Jean Monnet of Saint Etienne EA3065   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Anti xa; Anticoagulant agents; Apixaban; Blood coagulation tests; Multicenter study

Indexed keywords

APIXABAN;

ANTI FACTOR XA ASSAY; ARTICLE; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; COAGULOMETER; CONCENTRATION (PARAMETERS); HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LABORATORY TEST; MASS SPECTROMETRY; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME;

ANTI-XA; ANTICOAGULANT AGENTS; APIXABAN; BLOOD COAGULATION TESTS; MULTICENTER STUDY;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG MONITORING; FACTOR V; FACTOR XA; FRANCE; HUMANS; LABORATORY PROFICIENCY TESTING; OBSERVER VARIATION; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE OF TESTS; PROTHROMBIN; PROTHROMBIN TIME; PYRAZOLES; PYRIDONES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 84893185400     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-06-0470     Document Type: Article

References (26)

1. Alves C, Batel-Marques F, Macedo AF. Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis. J Cardiovasc Pharmacol Ther 2012; 17: 266-276.
2. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
3. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
4. Agnelli G, Buller HR, Cohen A, et al. Apixaban for Extended Treatment of Venous Thromboembolism. N Engl J Med 2013; 368: 699-708.
5. Agnelli G, Buller HR, Cohen A, et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N Engl J Med 2013; Epub ahead of print.
6. Baglin T, Hillarp A, Tripodi A, et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; Epub ahead of print.
7. Garcia D, Barrett YC, Ramacciotti E, et al. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 2013; 11: 245-252.
8. Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-1271.
9. Becker RC, Alexander JH, Newby LK, et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost 2010; 104: 976-983.
10. Douxfils J, Chatelain C, Chatelain B, et al. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013; 110: 283-294
11. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013; 75: 476-487.
12. Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacody-namics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013; Epub ahead of print.
13. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Anti-thrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 44-88.
14. Sié P, Samama CM, Godier A, et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemo-stasis and the French Study Group on Thrombosis and Haemostasis. Arch Car-diovasc Dis 2011; 104: 669-676.
15. Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chro-mogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387.
16. Mani H, Rohde G, Stratmann G, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 2012; 108: 191-198.
17. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138-143.
18. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013; 75: 476-487.
19. Barrett YC, Wang J, Song Y, et al. A randomised assessment of the pharmacoki-netic, pharmacodynamic and safety interaction between apixaban and enoxapa-rin in healthy subjects. Thromb Haemost 2012; 107: 916-924.
20. Samama MM, Martinoli J-L, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
21. Douxfils J, Mullier F, Loosen C, et al. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of riva-roxaban and review of the literature. Thromb Res 2012; 130: 956-966.
22. Mani H, Hesse C, Stratmann G, et al. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Hae-most 2011; 106: 156-164.
23. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Hae-most 2011; 9: 133-139.
24. Freyburger G, Macouillard G, Labrouche S, et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011; 127: 457-465.
25. Harenberg J, Krämer R, Giese C, et al. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis 2011; 32: 267-271.
26. Harenberg J, Marx S, Weiss C, et al. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of riva-roxaban. J Thromb Haemost 2012; 10: 1433-1436.